11A
ABBV icon

10-15 Associates’s AbbVie ABBV Stock Holding History

10-15 Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$2.5M Sell
28,537
-142,305
-83% -$13.4M 0.48% 50
2020
Q2 		$16.8M Buy
170,842
+6,242
+4% +$550K 3.38% 4
2020
Q1 		$12.5M Buy
164,600
+21,203
+15% +$1.81M 2.92% 8
2019
Q4 		$12.7M Sell
143,397
-3,001
-2% -$249K 2.4% 15
2019
Q3 		$11.1M Sell
146,398
-628
-0.4% -$43.1K 2.28% 21
2019
Q2 		$10.7M Buy
147,026
+6,656
+5% +$523K 2.32% 22
2019
Q1 		$11.3M Buy
140,370
+8,471
+6% +$693K 2.43% 18
2018
Q4 		$12.2M Buy
131,899
+6,337
+5% +$557K 2.98% 10
2018
Q3 		$11.9M Buy
125,562
+6,593
+6% +$625K 2.66% 12
2018
Q2 		$11M Buy
118,969
+98,993
+496% +$9.67M 2.48% 17
2018
Q1 		$1.89M Sell
19,976
-5,144
-20% -$565K 0.45% 53
2017
Q4 		$2.43M Sell
25,120
-317
-1% -$29.9K 0.58% 45
2017
Q3 		$2.26M Buy
25,437
+132
+0.5% +$10K 0.57% 46
2017
Q2 		$1.83M Buy
25,305
+1,233
+5% +$82.9K 0.52% 46
2017
Q1 		$1.57M Buy
24,072
+568
+2% +$35.7K 0.43% 54
2016
Q4 		$1.47M Buy
23,504
+1,762
+8% +$108K 0.41% 59
2016
Q3 		$1.37M Buy
21,742
+10,032
+86% +$649K 0.38% 60
2016
Q2 		$725K Buy
11,710
+6,465
+123% +$394K 0.21% 71
2016
Q1 		$299K Sell
5,245
-70
-1% -$3.9K 0.09% 88
2015
Q4 		$315K Buy
5,315
+140
+3% +$8.06K 0.09% 94
2015
Q3 		$281K Sell
5,175
-175
-3% -$11.4K 0.1% 92
2015
Q2 		$359K Sell
5,350
-200
-4% -$13.1K 0.11% 92
2015
Q1 		$324K Buy
+5,550
New +$335K 0.11% 99

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

10-15 Associates's ABBV Position: Q3 2020 in Review

10-15 Associates reduced its AbbVie (ABBV) stake by 83% in Q3 2020, selling an estimated $13.4M and leaving 28,537 shares worth $2.5M. The position accounts for 0.48% of the portfolio, ranked #50.

10-15 Associates first reported a position in ABBV in Q1 2015 and has held it in 23 quarters since. The position peaked at $16.8M in Q2 2020. 2,367 funds tracked by Wall St. Rank hold ABBV as of Q3 2020.

  • 10-15 Associates held 28,537 shares of AbbVie worth $2.5M as of Q3 2020.
  • 10-15 Associates sold 142,305 AbbVie shares in Q3 2020, an estimated $13.4M.
  • AbbVie made up 0.48% of 10-15 Associates's portfolio in Q3 2020, its #50 holding.
  • 10-15 Associates first reported a position in AbbVie in Q1 2015 and has held it in 23 quarters since.
  • 10-15 Associates's AbbVie position peaked at $16.8M in Q2 2020.
  • 2,367 funds tracked by Wall St. Rank held AbbVie as of Q3 2020.

Based on 10-15 Associates's 13F filing for Q3 2020, filed 13 Oct 2020.